Neal George Anderson

US Patent:

6515170, Feb 4, 2003

Filed:

Apr 26, 2001

Appl. No.:

09/843226

Inventors:

Ramesh N. Patel - Bridgewater NJ
Amit Banerjee - St. Louis MO
Venkata B. Nanduri - East Brunswick NJ
Steven L. Goldberg - Basking Ridge NJ
Robert M. Johnston - Whitehouse Station NJ
Thomas P. Tully - Middlesex NJ
Laszlo J. Szarka - East Brunswick NJ
Shankar Swaminathan - North Brunswick NJ
John J. Venit - North Brunswick NJ
Jerome L. Moniot - Chester NJ
William J. Winter - New Brunswick NJ
Neal G. Anderson - Stockton NJ
David A. Lust - Roosevelt NJ
Gerard Crispino - Princeton NJ
Sushil K. Srivastava - Dayton NJ

Assignee:

Bristol-Myers Squibb Co. - Princeton NJ

International Classification:

C07C 3200

US Classification:

562432, 562433, 562426, 562485, 562400

Abstract:

The present invention concerns an enzymatic oxidative deamination process of a dipeptide monomer to prepare an intermediate useful to prepare compounds having endopeptidase and angiotensin converting enzyme inhibition activity.

US Patent:

50268732, Jun 25, 1991

Filed:

Nov 6, 1989

Appl. No.:

7/432028

Inventors:

Neal G. Anderson - Somerset NJ
David A. Lust - Roosevelt NJ
Barbara J. Bennett - North Brunswick NJ
Alan F. Feldman - Philadelphia PA
Robert E. Polomski - Franklin Park NJ

Assignee:

E. R. Squibb & Sons, Inc. - Princeton NJ

International Classification:

C07D20708

US Classification:

548533

Abstract:

A process is disclosed for direct isolation of captopril from a substrate of the formula ##STR1## wherein R is lower alkyl or lower alkoxy. In this process, the substrate is first treated with an aqueous alkali metal hydroxide capable of forming a water-soluble salt of the substrate, wherein the alkali metal hydroxide has a concentration of 4M or greater. The substrate is then neutralized, preferably with a mineral acid. By this process, captopril may be directly crystallized from an aqueous solution, avoiding the prior art use of organic solvents and zinc treatment to reduce levels of sulfide and disulfide impurities, respectively. In an alternative embodiment, neutralization is carried out by use of a hydrogen-supplying ion exchange resin.

US Patent:

49122304, Mar 27, 1990

Filed:

Sep 16, 1988

Appl. No.:

7/245086

Inventors:

Neal G. Anderson - Somerset NJ
Christopher M. Cimarusti - Somerset NJ
David A. Lust - Roosevelt NJ

Assignee:

E. R. Squibb & Sons, Inc. - Princeton NJ

International Classification:

C07D20700

US Classification:

548533

Abstract:

A process is provided for inverting a hydroxy function of a L-trans-hydroxy proline derivative to the corresponding L-cis-hydroxy proline sulfonate by a Modified Mitsunobu reaction process.

US Patent:

48269735, May 2, 1989

Filed:

Dec 10, 1985

Appl. No.:

6/807374

Inventors:

Neal G. Anderson - Somerset NJ
Carl F. Anderson - North Brunswick NJ

Assignee:

E. R. Squibb & Sons, Inc. - Princeton NJ

International Classification:

C07D41712

US Classification:

540355

Abstract:

The crystalline delta(. delta. )-form of [3S-[3. alpha. (Z),-4. beta. ]]-3-[[(2-amino-4-thiazolyl) [(1-carboxy-1-methylethoxy)imino]acetyl]amino]-4-methyl-2-oxo-1-azetidines ulfonic acid is prepared.

US Patent:

61629227, Dec 19, 2000

Filed:

Jan 19, 1999

Appl. No.:

9/233238

Inventors:

Neal G. Anderson - Stockton NJ
Rajendra P. Deshpande - Neshanic Station NJ
Jerome L. Moniot - Chester NJ

Assignee:

Bristol-Myers Squibb Co. - Princeton NJ

International Classification:

C07D23502

US Classification:

5483007

Abstract:

Disclosed is a process for preparing N-substituted heterocyclic derivatives and its salts using phase transfer catalysis.